Business
2021.11.12
Awarded the 3rd prize of the Boehringer Ingelheim Innovation Prize, 2021
Business
2021.11.11
IP6K inhibitor(SCO-006)information has been updated
Paper
2021.08.19
Publication of a preclinical study: Inositol hexakisphosphate kinase (IP6K) is crucial in regulating plasma phosphate levels in vivo, and SCO-006-mediated IP6K inhibition is a potential novel treatment strategy against hyperphosphatemia
Paper
2021.07.29
Publication of a clinical phase 1 study: SCO-267, a GPR40 full agonist, is safe and well-tolerated, exhibits good potential for once-daily dosing, and improves glycemic control in humans
Business
2021.06.28
The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions – American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial
Business
2021.06.01
Huadong and SCOHIA PHARMA Announce Strategic Collaboration to Develop, Manufacture and Commercialize SCO-094 in Asia Pacific
Business
2021.05.28
SCOHIA initiates a phase 1 study on an SSTR5 antagonist (SCO-240)
Publication
2021.04.28
Presentation of new preclinical data of GLUT5 inhibitor at the Experimental Biology 2021: GLUT5 inhibition is a novel strategy to treat fructose-induced diseases
Paper
2021.02.08
Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models
Paper
2020.12.23
Publication of a preclinical study: the enteropeptidase inhibitor SCO-792 is therapeutically effective for improving renal function in a nondiabetic rat model of chronic kidney disease
Page Top